Alvotech (ALVO) Common Equity (2020 - 2026)
Alvotech's (ALVO) quarterly Common Equity came in at -$191.5 million in Q2 2026, down 10.47% on a YoY basis from -$213.9 million in Q2 2025, and up 32.17% quarter-over-quarter from -$282.3 million in Q1 2026.
Analysis
Alvotech (ALVO) Common Equity (2020 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Common Equity for 7 consecutive years, with -$191.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Common Equity fell 10.47% year-over-year to -$191.5 million; the trailing twelve-month figure through Jun 2026 stood at -$191.5 million (down 10.47% YoY), and the FY2025 full-year result was -$284.5 million, up 31.08% from the prior year.
- Common Equity rose to -$191.5 million in Q2 2026 per ALVO's latest filing, from -$282.3 million in the prior quarter.
- Across five years, Common Equity topped out at -$173.3 million in Q2 2025 and bottomed at -$932.5 million in Q4 2023.
- Historically, Common Equity has averaged -$432.1 million across 5 years, with a median of -$412.8 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Common Equity plunged 316.2% in 2022, then soared 71.39% in 2025.
- Over 5 years, Common Equity stood at -$564.4 million in 2022, then sank by 65.21% to -$932.5 million in 2023, then soared by 55.73% to -$412.8 million in 2024, then surged by 31.08% to -$284.5 million in 2025, then soared by 32.69% to -$191.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$191.5 million, -$282.3 million, and -$284.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 7.76 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 14.26 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 4.08 Bn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 33.02 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | -1.77 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -191.48 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 597.21 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 768.16 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 42.44 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | 4.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -191.48 Mn |
| Mar 31, 2026 | -282.31 Mn |
| Dec 31, 2025 | -284.49 Mn |
| Sep 30, 2025 | -412.77 Mn |
| Jun 30, 2025 | -173.33 Mn |
| Mar 31, 2025 | -412.77 Mn |
| Dec 31, 2024 | -412.77 Mn |
| Sep 30, 2024 | -343.71 Mn |
| Jun 30, 2024 | -605.92 Mn |
| Mar 31, 2024 | -658.83 Mn |
| Dec 31, 2023 | -932.49 Mn |
| Jun 30, 2023 | -478.54 Mn |
| Dec 31, 2022 | -564.42 Mn |
| Jun 30, 2022 | -296.22 Mn |
| Dec 31, 2021 | -135.61 Mn |
| Dec 31, 2020 | -867.24 Mn |